IONIS PHARMACEUTICALS INC
About IONIS PHARMACEUTICALS INC
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $943.7M
- Net income
- -$381.4M
- Total assets
- $3.5B
- Market cap
- $12.3B
- Gross margin
- 98.3%
- Operating margin
- -40.4%
- Net margin
- -40.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $943.7M
- Cost of revenue
- $15.9M
- Gross profit
- $927.8M
- Operating expenses
- $1.3B
- Operating income
- -$381.7M
- Income tax
- $1.8M
- Net income
- -$381.4M
- EPS (basic)
- $-2.38
- EPS (diluted)
- $-2.38
Balance sheet
- Total assets
- $3.5B
- Current assets
- $3.0B
- Total liabilities
- $3.0B
- Current liabilities
- $781.6M
- Shareholders’ equity
- $489.1M
Cash flow
- Operating cash flow
- -$268.6M
- Investing cash flow
- -$277.8M
- Financing cash flow
- $675.8M
- Net cash flow
- $129.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $12.3B
- EPS (diluted)
- $-2.38
- Shares outstanding
- 167.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 17, 1991
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $381.4M in FY2025.
- Revenue grew 16% from FY2021 to FY2025.
- Gross margin of 98.3%, net margin -40.4%.
- Trading 15% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review IONIS PHARMACEUTICALS INC.
Write a review
News about IONIS PHARMACEUTICALS INC
News & sentiment via Polygon.io
